Appendix JForest plots

Publication Details

The forest plots are presented with the same table numbers as the abbreviated GRADE tables in the main text of the full guideline to assist cross-referencing.

Chapter 4. Physical therapy (physiotherapy and/or occupational therapy)

Review question

What is the effectiveness of physical therapy (physiotherapy and/or occupational therapy) interventions in children with spasticity with or without other motor disorders (dystonia, muscle weakness and choreoathetosis) caused by a non-progressive brain disorder?

There are no forest plots for this review question because no meta-analyses were conducted for the guideline review.

Chapter 5. Orthoses

Review question

What is the effectiveness of orthotic interventions (for example, ankle-foot orthoses, knee splints, and upper limb orthoses) as compared to no orthoses to optimise movement and function, to prevent or treat contractures in children with spasticity and with or without other motor disorders caused by a non-progressive brain disorder?

There are no forest plots for this review question because no meta-analyses were conducted for the guideline review.

Chapter 6. Oral drugs

Review question

What is the effectiveness of oral medications including baclofen, benzodiazepines (diazepam, nitrazepam, clonazepam), tizanidine, dantrolene, clonidine, trihexyphenidyl, tetrabenazine and levodopa in the treatment of spasticity and other motor disorders (dystonia, muscle weakness and choreoathetosis) caused by a non-progressive brain disorder in children and young people?

There are no forest plots for this review question because no meta-analyses were conducted for the guideline review.

Chapter 7. Botulinum toxin

Review question

What is the effectiveness of the long-term use of intramuscular BoNT-A or BoNT-B in combination with other interventions (physical therapy or orthoses) as compared to other interventions in reducing spasticity, maintaining motor function and preventing secondary complications in children and young people with spasticity with or without other motor disorders (dystonia, muscle weakness and choreoathetosis) caused by a non-progressive brain disorder?

Forest plots for the meta-analyses reported in Tables 7.1, 7.3 and 7.6 are presented in Hoare 2010.

Table J.7.5. Evidence profile for botulinum toxin type A and physical therapy compared with physical therapy alone; upper limb; quality of life assessment

Chapter 8. Intrathecal baclofen

Review questions

In children and young people with spasticity due to a non-progressive brain disorder does ITB testing help to identify those likely to benefit from CITB?

In children and young people with spasticity due to a non-progressive brain disorder what are the benefits and risks of CITB?

There are no forest plots for these review questions because no meta-analyses were conducted for the guideline reviews.

Chapter 9. Orthopaedic surgery

Review questions

What is the effectiveness of orthopaedic surgery in preventing or treating musculoskeletal deformity in children with spasticity caused by a non-progressive brain disorder?

What is the effectiveness of SEMLS in managing musculoskeletal deformity in children with spasticity caused by a non-progressive brain disorder?

There are no forest plots for this review question because no meta-analyses were conducted for the guideline review.

Chapter 10. Selective dorsal rhizotomy

Review question

What is the clinical effectiveness of SDR in children and young people with spasticity caused by a non-progressive brain disorder?

Table J.10.2. Evidence profile for selective dorsal rhizotomy and therapy compared with therapy only in children with diplegia; functioning assessment